Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Memory Pharmaceuticals
Nutley or Montvale, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Memory Pharmaceuticals developed small molecule drug candidates targeting central nervous system disorders, with its lead programs focused on nicotinic alpha-7 agonists for Alzheimer's disease and schizophrenia. At the time of its acquisition by Roche in late 2008, its most advanced program was in Phase II clinical trials for these indications[1][3].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (notably nicotinic alpha-7 agonists)[1][3]
- Industry
- Biotech
02
Partnerships
Roche was a key partner prior to full acquisition; partnered on development of CNS drug candidates[1].
Beyond the preview
Go deeper on Memory Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Memory Pharmaceuticals.